Patients already included in one of the following ongoing vaccine observational subprotocols: SARS-CoV-2 cellular and humoral immune response following vaccination of kidney transplant recipients and healthy controls SARS-CoV-2 serological vaccine response in patients at Oslo University Hospital Vaccine responses in MS: Nevrovax. A Norwegian study of vaccine response to COVID-19 vaccines in patients using immunosuppressive medication within rheumatology and gastroenterology – The Nor-vaC study Immunological response to Covid-19 vaccination in Lymphoma patients treated with Rituximab and in Bone marrow Transplanted patients. Patients with an interval between the first and second vaccine dose according to drug label, 3 weeks for Comirnaty and 4 weeks for SpikeVax. Patients with no or impaired humoral immune response more than 3 weeks after two doses of SARS-CoV-2 mRNA vaccine (SARS-CoV-2 SPIKE IgG ≤100 AU). Available for vaccination at a few centralized centers (OUS, AHUS, Diakonhjemmet Hospital, HUS). Not participating in therapeutical intervention studies. Adult patients (≥18 years). For fourth dose: Solid organ transplant recipients with no or impaired humoral immune response 4 weeks after three doses of SARS-CoV-2 mRNA vaccine (SARS-CoV-2 SPIKE IgG ≤100 AU).

Patients already included in one of the following ongoing vaccine observational subprotocols: SARS-CoV-2 cellular and humoral immune response following vaccination of kidney transplant recipients and healthy controls SARS-CoV-2 serological vaccine response in patients at Oslo University Hospital Vaccine responses in MS: Nevrovax. A Norwegian study of vaccine response to COVID-19 vaccines in patients using immunosuppressive medication within rheumatology and gastroenterology – The Nor-vaC study Immunological response to Covid-19 vaccination in Lymphoma patients treated with Rituximab and in Bone marrow Transplanted patients. Patients with an interval between the first and second vaccine dose according to drug label, 3 weeks for Comirnaty and 4 weeks for SpikeVax. Patients with no or impaired humoral immune response more than 3 weeks after two doses of SARS-CoV-2 mRNA vaccine (SARS-CoV-2 SPIKE IgG ≤100 AU). Available for vaccination at a few centralized centers (OUS, AHUS, Diakonhjemmet Hospital, HUS). Not participating in therapeutical intervention studies. Adult patients (≥18 years). For fourth dose: Solid organ transplant recipients with no or impaired humoral immune response 4 weeks after three doses of SARS-CoV-2 mRNA vaccine (SARS-CoV-2 SPIKE IgG ≤100 AU).

 Patients with impaired humoral immune response to SARS-CoV-2 vaccination.  Adult patients (≥18 years).  Signed informed consent

 Patients with impaired humoral immune response to SARS-CoV-2 vaccination.  Adult patients (≥18 years).  Signed informed consent